TNF and Diplopia: A total of 11.1% of patients (n = 2) experienced adverse events leading to treatment discontinuation: one patient reported diplopia which occurred after 14 months of anti-TNF-α therapy, while another had a worsening of vitreous inflammation and opacity after 15 months of treatment.